|
1
|
Morgan RJ Jr, Alvarez RD, Armstrong DK,
Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson
D, Gray HJ, et al: Epithelial ovarian cancer. J Natl Compr Canc
Netw. 9:82–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prat J: Ovarian carcinomas: Five distinct
diseases with different origins, genetic alterations, and
clinicopathological features. Virchows Arch. 460:237–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hensley CT, Wasti AT and DeBerardinis RJ:
Glutamine and cancer: Cell biology, physiology, and clinical
opportunities. J Clin Invest. 123:3678–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohamed A, Deng X, Khuri FR and Owonikoko
TK: Altered glutamine metabolism and therapeutic opportunities for
lung cancer. Clin Lung Cancer. 15:7–15. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhdanov AV, Waters AH, Golubeva AV,
Dmitriev RI and Papkovsky DB: Availability of the key metabolic
substrates dictates the respiratory response of cancer cells to the
mitochondrial uncoupling. Biochim Biophys Acta. 1837:51–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herrera Gonzalez KN, Lee J and Haigis MC:
Intersections between mitochondrial sirtuin signaling and tumor
cell metabolism. Crit Rev Biochem Mol Biol. 50:242–255. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuchs BC and Bode BP: Stressing out over
survival: Glutamine as an apoptotic modulator. J Surg Res.
131:26–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Medina MA, Sánchez-Jimenez F, Márquez J,
Quesada Rodriguez A and de Castro Nuñez I: Relevance of glutamine
metabolism to tumor cell growth. Mol Cell Biochem. 113:1–15. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fuchs BC and Bode BP: Amino acid
transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin
Cancer Biol. 15:254–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dolinska M, Dybel A, Zablocka B and
Albrecht J: Glutamine transport in C6 glioma cells shows ASCT2
system characteristics. Neurochem Int. 43:501–507. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kilberg MS, Stevens BR and Novak DA:
Recent advances in mammalian amino acid transport. Annu Rev Nutr.
13:137–165. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGivan JD and Pastor-Anglada M:
Regulatory and molecular aspects of mammalian amino acid transport.
Biochem J. 299:321–334. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanai Y and Hediger MA: The
glutamate/neutral amino acid transporter family SLC1: Molecular,
physiological and pharmacological aspects. Pflugers Arch.
447:469–479. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kekuda R, Prasad PD, Fei YJ,
Torres-Zamorano V, Sinha S, Yang-Feng TL, Leibach FH and Ganapathy
V: Cloning of the sodium-dependent, broad-scope, neutral amino acid
transporter Bo from a human placental choriocarcinoma cell line. J
Biol Chem. 271:18657–18661. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Geldermalsen M, Wang Q, Nagarajah R,
Marshall AD, Thoeng A, Gao D, Ritchie W, Feng Y, Bailey CG, Deng N,
et al: ASCT2/SLC1A5 controls glutamine uptake and tumour growth in
triple-negative basal-like breast cancer. Oncogene. 35:3201–3208.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Yang L, An H, Chang Y, Zhang W, Zhu
Y, Xu L and Xu J: High expression of solute carrier family 1,
member 5 (SLC1A5) is associated with poor prognosis in clear-cell
renal cell carcinoma. Sci Rep. 5:169542015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun HW, Yu XJ, Wu WC, Chen J, Shi M, Zheng
L and Xu J: GLUT1 and ASCT2 as predictors for prognosis of
hepatocellular carcinoma. PLoS One. 11:e01689072016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Hardie RA, Hoy AJ, van
Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder
M, Nagarajah R, et al: Targeting ASCT2-mediated glutamine uptake
blocks prostate cancer growth and tumour development. J Pathol.
236:278–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toda K, Nishikawa G, Iwamoto M, Itatani Y,
Takahashi R, Sakai Y and Kawada K: Clinical role of ASCT2 (SLC1A5)
in KRAS-mutated colorectal cancer. Int J Mol Sci. 18:pii:
E16322017. View Article : Google Scholar
|
|
22
|
Kasai N, Sasakawa A, Hosomi K, Poh TW,
Chua BL, Yong WP, So J, Chan SL, Soong R, Kono K, et al: Anti-tumor
efficacy evaluation of a novel monoclonal antibody targeting
neutral amino acid transporter ASCT2 using patient-derived
xenograft mouse models of gastric cancer. Am J Transl Res.
9:3399–3410. 2017.PubMed/NCBI
|
|
23
|
Hassanein M, Hoeksema MD, Shiota M, Qian
J, Harris BK, Chen H, Clark JE, Alborn WE, Eisenberg R and Massion
PP: SLC1A5 mediates glutamine transport required for lung cancer
cell growth and survival. Clin Cancer Res. 19:560–570. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hassanein M, Qian J, Hoeksema MD, Wang J,
Jacobovitz M, Ji X, Harris FT, Harris BK, Boyd KL, Chen H, et al:
Targeting SLC1a5-mediated glutamine dependence in non-small cell
lung cancer. Int J Cancer. 137:1587–1597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Q, Beaumont KA, Otte NJ, Font J,
Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM,
Jormakka M, et al: Targeting glutamine transport to suppress
melanoma cell growth. Int J Cancer. 135:1060–1071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Willems L, Jacque N, Jacquel A, Neveux N,
Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, et
al: Inhibiting glutamine uptake represents an attractive new
strategy for treating acute myeloid leukemia. Blood. 122:3521–3532.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wise DR and Thompson CB: Glutamine
addiction: A new therapeutic target in cancer. Trends Biochem Sci.
35:427–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Montero JC, Chen X, Ocaña A and Pandiella
A: Predominance of mTORC1 over mTORC2 in the regulation of
proliferation of ovarian cancer cells: Therapeutic implications.
Mol Cancer Ther. 11:1342–1352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dobbin ZC and Landen CN: The importance of
the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int
J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gallo-Oller G, Ordoñez R and Dotor J: A
new background subtraction method for Western blot densitometry
band quantification through image analysis software. J Immunol
Methods. 457:1–5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hammoudi N, Ahmed KB, Garcia-Prieto C and
Huang P: Metabolic alterations in cancer cells and therapeutic
implications. Chin J Cancer. 30:508–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang F, Zhao Y, Zhao J, Wu S, Jiang Y, Ma
H and Zhang T: Upregulated SLC1A5 promotes cell growth and survival
in colorectal cancer. Int J Clin Exp Pathol. 7:6006–6014.
2014.PubMed/NCBI
|
|
36
|
Shimizu K, Kaira K, Tomizawa Y, Sunaga N,
Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M,
et al: ASC amino-acid transporter 2 (ASCT2) as a novel prognostic
marker in non-small cell lung cancer. Br J Cancer. 110:2030–2039.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Noske A, Lindenberg JL, Darb-Esfahani S,
Weichert W, Buckendahl AC, Röske A, Sehouli J, Dietel M and Denkert
C: Activation of mTOR in a subgroup of ovarian carcinomas:
Correlation with p-eIF-4E and prognosis. Oncol Rep. 20:1409–1417.
2008.PubMed/NCBI
|
|
38
|
No JH, Jeon YT, Park IA, Kim YB, Kim JW,
Park NH, Kang SB, Han JY, Lim JM and Song YS: Activation of mTOR
signaling pathway associated with adverse prognostic factors of
epithelial ovarian cancer. Gynecol Oncol. 121:8–12. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaira K, Nakamura K, Hirakawa T, Imai H,
Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Tsukamoto N, Oyama T,
et al: Prognostic significance of L-type amino acid transporter 1
(LAT1) expression in patients with ovarian tumors. Am J Transl Res.
7:1161–1171. 2015.PubMed/NCBI
|
|
40
|
Yuan L, Sheng X, Willson AK, Roque DR,
Stine JE, Guo H, Jones HM, Zhou C and Bae-Jump VL: Glutamine
promotes ovarian cancer cell proliferation through the mTOR/S6
pathway. Endocr Relat Cancer. 22:577–591. 2015. View Article : Google Scholar : PubMed/NCBI
|
